-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1019 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Pancreatic Cancer Drug Details: CBP-1019 is under development for...
-
Product Insights
Sudoriferous (Sweat) Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Sudoriferous (Sweat) Gland Disorders - Drugs In Development, 2023’, provides an overview of the Sudoriferous (Sweat) Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sudoriferous (Sweat) Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Axillary Hyperhidrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Axillary Hyperhidrosis - Drugs In Development, 2023’, provides an overview of the Axillary Hyperhidrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vascular Dementias – Drugs In Development, 2023
Global Markets Direct’s, ‘Vascular Dementias - Drugs In Development, 2023’, provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
United Kingdom (UK) Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
UK Defense Market Report Overview The United Kingdom (UK) defense budget is worth $62.8 billion in 2023. The country’s defense budget is anticipated to rise in steady and gradual annual increments, registering a CAGR of more than 4% during 2024-2028. Despite the challenges of COVID recovery, energy insecurity, and sustained inflation, British foreign policy retains ambitions and international commitments that make this sustained increase a likelihood as the British military redoubles deployments in Europe and elsewhere. Despite Brexit, the UK...
-
Product Insights
Windpark Hogezandse Polder
Windpark Hogezandse Polder is an Onshore Wind project located in South Holland, Netherlands. The project is owned by Eneco Holding NV and was developed by De Wolff Verenigde Bedrijven BV; Eneco Holding NV. The project came online in 2019. Empower your strategies with our Windpark Hogezandse Polder report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glycopyrrolate in Axillary Hyperhidrosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Glycopyrrolate in Axillary Hyperhidrosis Drug Details: Glycopyrronium bromide is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Obicetrapib in Atherosclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obicetrapib in Atherosclerosis Drug Details: Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for Alzheimer’s...
-
Product Insights
Wolff Co – Phoenix Apartment Complex – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wolff Co - Phoenix Apartment Complex - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Wolff Urban Dev – 1431 Jefferson Street Hotel – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wolff Urban Dev - 1431 Jefferson Street Hotel - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...